Open | 0.5672 |
Previous Close | 0.8657 |
Volume | 15.85 Mil. |
Average Volume | 1.03 Mil. |
Day's Range | 0.4319 โ 0.5811 |
52 Week Range | 0.43-11.18 |
Market Cap | 7.72 Mil. |
Moving Average (50) | 0.98652 |
Moving Average (200) | 1.75776 |
Earnings per Share (EPS) | -2.8 |
Price/Earnings (PE) | -0.17 |
Shares Outstanding | 15.92 Mil. |
Earnings Date | Aug 04, 2025 |
Beta | 3.442 |
Last Dividend | 0 |
GOVX Latest News
|
|
|
|
|
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
About GeoVax Labs | |
Industry | Biotechnology |
Sector | Healthcare |
Number of Employees | 17 |
Website & Executive | |
Website | https://www.geovax.com |
CEO (Chief Executive Officer) | David Alan Dodd |
IPO date | 2020-09-25 |
Contact | |
Country | US |
Address | 1900 Lake Park Drive |
City | Smyrna |
State | GA |
Phone | 678 384 7220 |
Zip Code | 30080 |
Other Identifiers | |
CIK | 0000832489 |
ISIN | US3736786068 |
CUSIP | 373678507 |